Cargando…

Mechanisms regulating PD-L1 expression on tumor and immune cells

BACKGROUND: The PD-1/PD-L1 checkpoint is a central mediator of immunosuppression in the tumor immune microenvironment (TME) and is primarily associated with IFN-g signaling. To characterize other factors regulating PD-L1 expression on tumor and/or immune cells, we investigated TME-resident cytokines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shuming, Crabill, George A., Pritchard, Theresa S., McMiller, Tracee L., Wei, Ping, Pardoll, Drew M., Pan, Fan, Topalian, Suzanne L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858680/ https://www.ncbi.nlm.nih.gov/pubmed/31730010 http://dx.doi.org/10.1186/s40425-019-0770-2

Ejemplares similares

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
por: Lipson, Evan J, et al.
Publicado: (2015)

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
por: Lipson, Evan J, et al.
Publicado: (2014)

YAP Attenuates CD8 T Cell-Mediated Anti-tumor Response
por: Lebid, Andriana, et al.
Publicado: (2020)

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
por: Anagnostou, Valsamo, et al.
Publicado: (2020)

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
por: Miller, Natalie J., et al.
Publicado: (2018)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target
por: Pan, Fan, et al.
Publicado: (2012)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
por: Giraldo, Nicolas A., et al.
Publicado: (2018)

Cyclic dinucleotides (CDNs) anti-tumors response by activating DC and NK cell crosstalk
por: Fu, Juan, et al.
Publicado: (2014)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
por: Zaslavsky, Alexander B., et al.
Publicado: (2020)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
por: Li, Hui, et al.
Publicado: (2020)

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
por: Zhou, Kaijian, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
por: Filippone, A., et al.
Publicado: (2022)

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018)

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
por: Wang, Yiting, et al.
Publicado: (2018)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
por: Koirala, Pratistha, et al.
Publicado: (2016)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
por: Fan, Yangwei, et al.
Publicado: (2016)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
por: Weyerer, Veronika, et al.
Publicado: (2021)

PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity
por: Gordon, Sydney R., et al.
Publicado: (2017)

MDSCs enhance tumor cell proliferation in a caspase-1 related inflammasome cytokines dependent way
por: Zeng, Qi, et al.
Publicado: (2015)

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
por: Black, Madison, et al.
Publicado: (2016)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
por: Keber, Corinna U., et al.
Publicado: (2022)

Immunotherapy earns its spot in the ranks of cancer therapy
por: Pardoll, Drew, et al.
Publicado: (2012)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Persistent brainstem abscess requiring repeat microsurgical drainage: case report
por: Shoap, Wesley, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8njj13ijlvoeo8hdjlthj4sufd